Key Takeaways
Extended Takeaways
- In this VA outpatient cohort, mirtazapine 3.75 mg was used after lack of efficacy with traditional sleep aids, supporting it as a practical next-step option for treatment-resistant insomnia rather than a first-line intervention.
- Among all 53 veterans evaluated, 47% had an ISI reduction of greater than 7 points and 32% reached recovery with an ISI score of 7 or lower, suggesting that a meaningful minority may achieve remission within 1–3 months.
- For patients with follow-up data after completing treatment, mean ISI decreased from 20.4 [4.58] at baseline to 8.9 [6.76] at 1–3 months, and the mean change was 11.3 [6.46], indicating a large short-term improvement in perceived insomnia severity.
- All veterans who completed treatment had either a constant or decreased ISI score at 1–3 months, which may help clinicians frame expectations that early worsening was not observed in treatment completers in this sample.
- Interpret response estimates cautiously because 17 of the 53 veterans evaluated did not complete treatment, and the study lacked a control group, limiting conclusions about comparative efficacy and long-term benefit.